Netsmart Technologies

ntst.com →

est. 2Y upside i

Healthcare

Rank

#3551

Sector

Healthcare IT

Est. Liquidity

~2Y

Data Quality

Data: Medium

Netsmart equity is essentially priced at its expected sale value of $5B (~8.5x revenue of $585M), leaving employees who receive equity today with near-zero probability-weighted upside (~0%) unless a strategic acquirer pays a meaningful 30–40% premium.

Last updated: May 13, 2026

Bull (12%)+40%

A competitive M&A auction—most plausibly a large strategic such as Oracle Health, UnitedHealth, or a scaled healthcare IT consolidator—drives an exit at ~$7B (~12x forward revenue of $585M), roughly 40% above the current $5B mark. AI product traction (AlphaCoding, TheraOffice integrations) validates a premium multiple and accelerates the deal close to within 12 months of the announced process.

Base (53%)+8%

The 2026 sale process closes at a modest premium of ~$5.3–5.5B (~9x revenue), consistent with analyst estimates and comparable niche healthcare-IT PE exit multiples. Employees realize ~8% gross upside within 18 months as GI Partners and TA Associates complete their exit, though common equity is exposed to any preference stack ahead of it.

Bear (35%)-25%

The sale process stalls or reprices to ~$3.75B (~6.4x revenue) amid buyer concern over Epic/Cerner's accelerating expansion into behavioral health and post-acute care, or macro-driven multiple compression in healthcare IT. A PE-to-PE recapitalization at a discount leaves equity holders ~25% underwater versus their $5B entry valuation.

Est. time to liquidity~1.5 years

Preference Stack Risk

moderate

Funding Intensity

11%

Using the 2018 secondary buyout round of $566.6M against the $5B current valuation implies ~11.3% funding intensity by disclosed equity—within the moderate (5–15%) band—but a typical PE LBO layers an additional estimated $500M–$1.5B of debt ahead of common equity that subordinates employee shares in any sub-$5B exit.

Dilution Risk

low

Post-LBO PE-owned companies rarely issue material new equity tranches; additional dilution is unlikely given the imminent exit process, making strike-price or grant-price dilution the primary concern rather than share count expansion.

Secondary Liquidity

limited

No established secondary market exists for Netsmart employee equity, but the active GI Partners/TA Associates sale process effectively functions as the sole near-term liquidity event, concentrating all upside and downside into a single binary outcome.

Other — 7 roles

View all 7 open roles at Netsmart Technologies →

Last updated: February 18, 2026

Questions to Ask at the Interview

Strategic questions based on Netsmart Technologies's data — designed to show you've done your homework.

1
“How is Netsmart specifically defending its behavioral health and post-acute EHR market share against Epic's expanding community-care and post-acute modules—and what is your net revenue retention rate in those segments over the past two years?”
2
“Can you share revenue growth rate and EBITDA margin for fiscal 2024 and 2025, and how does the India engineering hub affect your R&D cost structure and product release velocity?”
3
“Given the reported 2026 sale process, what is the exact equity treatment for RSU and option holders at a change-of-control—is there full acceleration, what is the liquidation waterfall above $5B, and how much of the cap table is held by management versus PE sponsors?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.